Clinical Outcomes Among Patients With Metastatic Pancreatic Ductal Adenocarcinoma Treated With Liposomal Irinotecan

BACKGROUND: The NAPOLI-1 trial demonstrated that liposomal irinotecan in combination with fluorouracil (5-FU) and leucovorin (LV) prolonged survival with a manageable safety profile in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Kenneth H., Hendifar, Andrew E., Alese, Olatunji B., Draper, Amber, Abdelrahim, Maen, Burns, Ethan, Khan, Gazala, Cockrum, Paul, Bhak, Rachel H., Nguyen, Catherine, DerSarkissian, Maral, Duh, Mei Sheng, Bahary, Nathan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319949/
https://www.ncbi.nlm.nih.gov/pubmed/34336666
http://dx.doi.org/10.3389/fonc.2021.678070

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8319949/
https://www.ncbi.nlm.nih.gov/pubmed/34336666
http://dx.doi.org/10.3389/fonc.2021.678070

Ejemplares similares